香港股市 已收市
  • 恒指

    20,175.62
    +93.19 (+0.46%)
     
  • 國指

    6,857.48
    +34.09 (+0.50%)
     
  • 上證綜指

    3,276.89
    -4.78 (-0.15%)
     
  • 滬深300

    4,191.15
    -2.39 (-0.06%)
     
  • 美元

    7.8357
    -0.0074 (-0.09%)
     
  • 人民幣

    0.8600
    +0.0006 (+0.07%)
     
  • 道指

    33,761.05
    +424.38 (+1.27%)
     
  • 標普 500

    4,280.15
    +72.88 (+1.73%)
     
  • 納指

    13,047.19
    +267.27 (+2.09%)
     
  • 日圓

    0.0584
    -0.0003 (-0.46%)
     
  • 歐元

    8.0400
    -0.0532 (-0.66%)
     
  • 英鎊

    9.5050
    -0.0640 (-0.67%)
     
  • 紐約期油

    91.88
    -2.46 (-2.61%)
     
  • 金價

    1,818.90
    +11.70 (+0.65%)
     
  • Bitcoin

    24,572.54
    +644.50 (+2.69%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

  • 噢!
    發生錯誤。
    請稍後再試一次。
·1 分鐘文章
在這篇文章中:
  • 噢!
    發生錯誤。
    請稍後再試一次。
  • Merck & Co Inc (NYSE: MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported, citing people familiar with the matter.

  • The Journal mentioned that the deal could be one of the largest takeovers of the year.

  • The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would bolster the pharma giant's cancer-drug portfolio, but no agreement was imminent.

  • Related: SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know.

  • The talks have picked up the pace. The companies are scheduled to meet this week, some people said.

  • WSJ could not tell if Merck had already submitted a formal offer for Seagen.

  • Merck may not be the only suitor, with others also eyeing the cancer-focused biotech, some people told WSJ.

  • The WSJ report notes the tricky nature of the deal, given the heightened risk of a regulatory challenge.

  • Through a 2020 deal, Merck acquired 5 million shares of Seagen for $1 billion. It also paid $600 million upfront for Seagen's LIV-1-targeting antibody-drug conjugates, including the most advanced ladiratuzumab vedotin for breast cancer and other solid tumors.

  • The companies have also teamed up on Seagen's HER2 small molecule drug Tukysa. Merck holds Tukysa rights in Asia, the Middle East, and Latin America.

  • Price Action: SGEN shares are up 3.45% at $180.00, and MRK stock is down 0.25% at $91.77 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

我們致力為用戶建立安全而有趣的平台,讓他們與志同道合的用戶聯繫交流。為改善我們的社群體驗,我們暫時停用文章留言功能